logo-alt.png
Global Thalassemia Treatment Market is estimated to be US$ 14.7 billion by 2030 with a CAGR of 10.40% during the forecast period - By PMI
April 30, 2021 10:05 ET | PMI
Covina, CA, April 30, 2021 (GLOBE NEWSWIRE) -- The Global Thalassemia Treatment Market accounted for US$ 2.3 billion in 2020 and is estimated to be US$ 14.7 billion by 2030 and is anticipated to...
logo-alt.png
Global Transthyretin Amyloidosis Treatment Market–Analysis and Demand with Forecast Overview to 2029 - by PMI
January 25, 2021 11:05 ET | PMI
Covina CA, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Robust pipeline of transthyretin amyloidosis treatment drugs is one of the major factors that is expected to propel growth of the market over the...
facit-logo
FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
January 29, 2019 07:00 ET | Triphase Accelerator
TORONTO, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class...
robbins-llp-logo-white-background1583450-1.png
Robbins Arroyo LLP is Investigating the Officers and Directors of Celgene Corporation (CELG) on Behalf of Shareholders
September 26, 2014 18:16 ET | Robbins LLP
SAN DIEGO and SUMMIT, N.J., Sept. 26, 2014 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Celgene Corporation breached...